Approach to patients with refractory coeliac disease

Area of Science:

• Gastroenterology
• Immunology
• Oncology

Background:

• Refractory coeliac disease (RCD) is a rare complication of coeliac disease (CD), characterized by persistent enteropathy despite a strict gluten-free diet.
• RCD is classified into type 1 (normal T-cells) and type 2 (aberrant T-cells), with distinct prognoses and management challenges.
• RCD type 2 carries a significant mortality risk and can progress to ulcerative jejunitis or enteropathy-associated T-cell lymphoma (EATL).

Approach:

• This review summarizes current and emerging management strategies for RCD type 2.
• It highlights the importance of differentiating RCD types for appropriate treatment selection.
• The article discusses various therapeutic options, including immunomodulation and targeted therapies.

Key Points:

• RCD type 2 requires specialized management due to its poor prognosis and potential complications.
• Treatment options for RCD type 2 are diverse and include immunosuppressants, chemotherapy, and stem cell transplantation.
• Accurate diagnosis and differentiation from other conditions are crucial for effective patient care.

Conclusions:

• Management of RCD type 2 remains challenging, necessitating a multidisciplinary approach.
• Further research is needed to optimize treatment protocols and improve outcomes for RCD type 2 patients.
• Early recognition and intervention are key to managing this rare but severe complication of coeliac disease.